Na Ji Eun, Kim Tae Jun, Lee Yeong Chan, Kim Ji Eun, Kim Eun Ran, Hong Sung Noh, Chang Dong Kyung, Kim Young-Ho
Department of Medicine, Inje University Haeundae Paik Hospital, Busan, Republic of Korea.
Division of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea.
Therap Adv Gastroenterol. 2022 Nov 21;15:17562848221137430. doi: 10.1177/17562848221137430. eCollection 2022.
Several studies have suggested an association between inflammatory bowel disease (IBD) and the risk of prostate cancer development. However, these findings are inconsistent, and studies based on Asian populations are limited.
We compared the risk of prostate cancer according to IBD status using the Korean National Health Insurance Service database.
A population-based retrospective cohort of age-matched 59,044 non-IBD patients and 14,761 IBD patients between January 2009 and December 2011 was analyzed up to December 2017.
The risk of prostate cancer was compared between patients with IBD and controls using the Cox proportional hazards regression model and Kaplan-Meier survival analysis.
During a median follow-up of 6 years, the incidence rate of prostate cancer was 264 per 100,000 person-years in non-IBD patients and 242 per 100,000 person-years in patients with IBD. IBD status was not associated with the risk of prostate cancer compared to non-IBD [adjusted hazard ratio (aHR) 0.93, 95% confidence interval (CI): 0.80-1.08, = 0.32). The cumulative incidence of prostate cancer did not differ by IBD status (non-IBD patients IBD patients: log-rank = 0.27; non-IBD patients ulcerative colitis Crohn's disease: log-rank = 0.42). In multivariate analysis, age was an independent risk factor for the development of prostate cancer (HR 1.03, 95% CI: 1.02-1.03, < 0.001).
In our population-based study, IBD status was not associated with the risk of prostate cancer.
多项研究表明炎症性肠病（IBD）与前列腺癌发生风险之间存在关联。然而，这些研究结果并不一致，且基于亚洲人群的研究有限。
我们利用韩国国民健康保险服务数据库，根据IBD状态比较前列腺癌风险。
对2009年1月至2011年12月期间年龄匹配的59,044例非IBD患者和14,761例IBD患者进行基于人群的回顾性队列研究，随访至2017年12月。
采用Cox比例风险回归模型和Kaplan-Meier生存分析比较IBD患者与对照组前列腺癌风险。
在中位随访6年期间，非IBD患者前列腺癌发病率为每10万人年264例，IBD患者为每10万人年242例。与非IBD相比，IBD状态与前列腺癌风险无关[调整后风险比（aHR）0.93，95%置信区间（CI）：0.80 - 1.08，P = 0.32]。前列腺癌累积发病率在IBD状态间无差异（非IBD患者 vs IBD患者：对数秩检验P = 0.27；非IBD患者 vs 溃疡性结肠炎患者 vs 克罗恩病患者：对数秩检验P = 0.42）。多因素分析中，年龄是前列腺癌发生的独立危险因素（HR 1.03, 95% CI: 1.02 - 1.03, P < 0.001）。
在我们基于人群的研究中，IBD状态与前列腺癌风险无关。
